Research Projects
Advancing Understanding Across the Lifespan
The Bench to Bassinet (B2B) Program was launched by the National Heart, Lung, and Blood Institute (NHLBI) in 2009 to break through the major barriers of translational research, identify the causes of human congenital heart disease (CHD), and ultimately improve outcomes for individuals with CHD.
Through the Congenital Heart Disease GEnetic NEtwork Study (CHD GENES), the Pediatric Cardiac Genomics Consortium (PCGC) enrolled and conducted genomic sequencing on over 14,000 participants with CHD and 18,000 family members to establish the largest CHD cohort to date with genomic and clinical data. Research conducted in partnership with these participants and families has advanced our understanding of which genes play a role in CHD and how the condition affects patients' health and care over time.
From CHD GENES to B2B CHANGE
CHD GENES remains an active research protocol with continued participant follow-up, data collection, and analysis. Building on this foundation, the Congenital Heart Disease Advancing New Understanding in GEnomics (B2B CHANGE) Cohort extends the study through ongoing clinical follow-up and detailed characterization of health outcomes over time. This next phase of research seeks to better understand how congenital heart disease, genetics, medical care, and life experiences influence long-term health and well-being for patients and their families.
Our Research Focus
Examples of long-term outcomes may include cognitive development, risk factors for other cardiovascular diseases, patients' physical activity, self-confidence, and mental health outcomes.
As more people with CHD live into adulthood, this may also help answer questions about whether pregnancy is safe for both mom and baby.
Research Objectives
Partnering with Patients and Families
Partner with patients, families, and the CHD community to sustain and expand this large, unique cohort of individuals with CHD across the lifespan.
Combining Clinical and Biological Data
Combine new information and biological samples with existing clinical and genetic data to give researchers the data, tools, and support they need to improve health and quality of life for people with CHD.
Looking Ahead
The B2B CHANGE Cohort will follow an estimated 6,000 current CHD GENES participants over time and collect detailed information about their health.
These data will help us learn how CHD continues to affect people in later childhood, adolescence, and young adulthood.
The cohort will also serve as a platform for other researchers to launch their own studies and answer important questions about how CHD develops and how a person's genetics influence health outcomes later in life.